Skip to main content
. Author manuscript; available in PMC: 2011 Mar 3.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 Mar 3;19(3):666–674. doi: 10.1158/1055-9965.EPI-09-1136

Table 5.

The estimatedprevalence (and standard error) of FBE in males and females, founders and non-founders under Mendelian dominant transmission

A. No polygenic component
Founder Non-founder Mean
Male 0.24% (0.01%) 0.96% (0.05%) 0.60% (0.03%)
Female 0.07% (0.005%) 0.30% (0.02%) 0.19% (0.01%)
Mean 0.14% (0.01%) 0.55% (0.03%)
B. Three polygenic loci
Founder Non-founder Mean
Male 0.21% (0.02%) 0.71% (0.04%) 0.48% (0.03%)
Female 0.06% (0.01%) 0.21% (0.02%) 0.14% (0.01%)
Mean 0.12% (0.01%) 0.40% (0.03%)